Form-483 (2)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NATCO Pharma provides clarification on ongoing litigation news, while Cipla addresses USFDA Form 483 inspectional observations at supply … | |||||||||||||||
NATCO Pharma provides clarification on ongoing litigation news, while Cipla addresses USFDA Form 483 inspectional observations at supply partner Pharmathen's Greece facility.
| |||||||||||||||
NATCO Pharma clarifies ongoing litigation with no current material impact, while Cipla addresses USFDA Form 483 observations at partner … | |||||||||||||||
NATCO Pharma clarifies ongoing litigation with no current material impact, while Cipla addresses USFDA Form 483 observations at partner facility Pharmathen manufacturing Lanreotide Injection.
| |||||||||||||||